Conferences - Results from #120

Viewing 121-140 of 11487 articles

ASCO 2024: Post-Progression Survival of Patients with mHSPC Who Received Darolutamide or Placebo: Post Hoc Analysis of ARASENS

ASCO 2024: ctDNA Fraction as a Predictor of Treatment Efficacy in a Randomized Phase 2 Trial of [177Lu] Lu-PSMA-617 Versus Cabazitaxel in mCRPC Progressing After Docetaxel

ASCO 2024: Enfortumab Vedotin with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: Analysis of Cisplatin-Eligible Population from EV-302/KEYNOTE-A39

ASCO 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma (aUC): Long-Term Outcomes from JAVELIN Bladder 100 in Patients with Low Tumor Burden

ASCO 2024: ENLIGHTED Phase 3 Study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer

ASCO 2024: A Phase 1/2 Study of EG-70 (Detalimogene Voraplasmid) Intravesical Monotherapy for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ASCO 2024: Rapid and Deep Prostate-Specific Antigen Response to Apalutamide plus ADT and Survival in Metastatic Castration-Sensitive Prostate Cancer in Real World Practice in the US (OASIS Project)

ASCO 2024: First-Line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma (RCC): An International Multi-Center Study

ASCO 2024: Prognostic Validation of a Digital Pathology-Based Multi-Modal Artificial Intelligence Biomarker in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the CHAARTED Trial (ECOG-ACRIN EA3805)

ASCO 2024: COBRA: Assessment of Safety and Efficacy of 64Cu-SAR-bisPSMA in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy

ASCO 2024: Study EV-103: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC) 2-Year Event-Free Survival and Safety Data for Cohort H

ASCO 2024: Association of Machine Learning–derived Histological Features with Transcriptomic Molecular Subtypes in Advanced Renal Cell Carcinoma

ASCO 2024: Enfortumab Vedotin with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Analysis of the Cisplatin-Ineligible Population from EV-302/KEYNOTE-A39

ASCO 2024: Long Term Cardiovascular Adverse Outcomes in Testicular Cancer Survivors: Real-World U.S. Population-Based Study

ASCO 2024: A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (A-DREAM/Alliance A032101)

ASCO 2024: Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ASCO 2024: Utility of ctDNA Burden as a Prognostic Biomarker for Efficacy in TALAPRO-2: A Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + Enzalutamide as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO 2024: Comparison of TKI and CPI Strategies as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma: Real-World Outcome Data from the German Research Platform CARAT

ASCO 2024: Discovery of a Novel Non-Negative Matrix Factorization-Based Homologous Recombination Deficiency Score and Subsequent Exploration in TALAPRO-2

ASCO 2024: 68Ga-PSMA PET/CT Response and Clinical Outcomes in Patients Treated with Enzalutamide as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer: Results of a Prospective Study

2
3
4
5
6
7
8
9
10
11